The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of ...

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

ArriVent BioPharma, Inc. ( (AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...